Abstract:Over 2 million people currently receive treatment with dialysis or a kidney transplant throughout the world. Thus, developing a new strategy to treat chronic kidney diseases is significant from the perspective of a health economic and the prevention of cardiovascular death. The small GTPase Rho and its effector Rho-kinase (ROCK) are involved in the pathogenesis of diabetic nephropathy. In chronic kidney diseases including diabetic nephropathy, tubulointerstitial fibrosis is known to be highly associated with renal outcome. We have previously reported that ROCK inhibition prevented the progression of diabetic nephropathy in murine models. With regards to ROCK, there are two isoforms, which are ROCK1 and ROCK2. ROCK1 has been shown to be involved in the endocytosis of albumin in tubular epithelial cells via megalin/cubilin-dependent mechanism. However, the role of renal tubular ROCK2 remains to be elucidated. The aim of this study is to reveal the role of renal tubular ROCK2 in the pathogenesis of chronic kidney disease. To this end, we used a tubulointerstitial injury model known as folic acid-induced nephropathy (FAN). Importantly, ROCK2 was elevated at protein levels in FAN group compared with vehicle-treated group. We next generated tubular specific ROCK2 knockout mouse (TR2KO) by crossing Ksp-Cre mice with mice containing two loxP sites flanking in Exon 3 of ROCK2. In the Ksp-Cre transgenic mice, Cre recombinase has been demonstrated to be expressed in tubules, collecting ducts, and thick ascending limbs. Compared with vehicle-treated group, collagen deposition in the kidneys of FAN group was highly elevated as revealed by Masson’s trichrome staining. The increased collagen deposition was significantly improved in TR2KO. Our findings indicate that ROCK2 regulates the progression of tubulointerstitial fibrosis. ROCK2 may be a potential therapeutic target for the prevention of chronic kidney disease. Disclosure K.Sekiguchi: None. K.Matoba: None. S.Ohashi: None. E.Mitsuyoshi: None. Y.Nagai: None. Y.Takeda: None. R.Nishimura: Speaker's Bureau; Sanofi K.K., Medicure Inc., Boehringer Ingelheim Inc., Takeda Pharmaceutical Company Limited, Kissei Pharmaceutical Co., Ltd., Novartis Pharma K.K., Eli Lilly Japan K.K., Novo Nordisk, Merck & Co., Inc., Abbott Japan Co., Ltd., Astellas Pharma Inc., Teijin Pharma Limited, Taisho Pharmaceutical Holdings Co., Ltd., Ono Pharmaceutical Co., Ltd., AstraZeneca.

Deletion of podocyte Rho-associated, coiled-coil-containing protein kinase 2 protects mice from focal segmental glomerulosclerosis

Amelioration of albuminuria in ROCK1 knockout mice with streptozotocin-induced diabetic kidney disease.

405-P: ROCK2 Activation and Its Role in Folic Acid–Induced Murine Model of Nephropathy

Blocking Ribosomal Protein S6 Phosphorylation Inhibits Podocyte Hypertrophy and Focal Segmental Glomerulosclerosis.

Genetic and Pharmacologic Targeting of Glycogen Synthase Kinase 3 Beta Reinforces the Nrf2 Antioxidant Defense Against Podocytopathy

Inhibition of ROCK2 alleviates renal fibrosis and the metabolic disorders in the proximal tubular epithelial cells.

Signaling Mechanism of Renal Fibrosis in Unilateral Ureteral Obstructive Kidney Disease in Rock1 Knockout Mice

The β isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy.

Activation of Rac-1 and RhoA Contributes to Podocyte Injury in Chronic Kidney Disease

The redox sensitive glycogen synthase kinase 3β suppresses the self-protective antioxidant response in podocytes upon oxidative glomerular injury.

Renin‐angiotensin blockade ameliorates the progression of glomerular injury in podocyte‐specific Ctcf knockout mice

Angiotensin II induces reorganization of the actin cytoskeleton and myosin light-chain phosphorylation in podocytes through rho/ROCK-signaling pathway*

Dissection of Glomerular Transcriptional Profile in Patients with Diabetic Nephropathy: SRGAP2a Protects Podocyte Structure and Function.

Autophagic inhibitor ROC-325 ameliorates glomerulosclerosis and podocyte injury via inhibiting autophagic flux in experimental FSGS mice

CRB2 Depletion Induces YAP Signaling and Disrupts Mechanosensing in Podocytes

Melanocortin Therapy Ameliorates Podocytopathy and Proteinuria in Experimental Focal Segmental Glomerulosclerosis Involving a Podocyte Specific Non-Mc1r-mediated Melanocortinergic Signaling.

Inhibition of RAC Attenuates Adriamycin-induced Podocyte Injury

Endothelial Mitochondrial Oxidative Stress Determines Podocyte Depletion in Segmental Glomerulosclerosis.

AKT2 is essential to maintain podocyte viability and function during chronic kidney disease

Rho-Rock Signal Pathway Regulates Microtubule-Based Process Formation Of Cultured Podocytes - A Rock Inhibitor Y-27632 Promoted Podocyte Process Elongation.

MAD2B-mediated cell cycle reentry of podocytes is involved in the pathogenesis of FSGS